Malignant pirates of the immune system

Nature Immunology

Volumn 12, Issue 10, 2011, Pages 933-940

  Rui, Lixin ^a   Schmitz, Roland ^a   Ceribelli, Michele ^a   Staudt, Louis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE DIFFERENTIATION FACTOR; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; INTERFERON REGULATORY FACTOR 4; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN BCL 6; TOLL LIKE RECEPTOR;

GENE EXPRESSION; GENE REARRANGEMENT; GERMINAL CENTER; HUMAN; IMMUNE SYSTEM; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOMATIC HYPERMUTATION; SURVIVAL; THYMUS LYMPHOMA;

ANIMALS; ANTIGENS, CD79; DNA-BINDING PROTEINS; HUMANS; IMMUNE SYSTEM; INTERFERON REGULATORY FACTORS; JANUS KINASE 2; LYMPHOMA; MYELOID DIFFERENTIATION FACTOR 88; ONCOGENES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 80053024575     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2094     Document Type: Review

References (114)

1. Lenz, G. & Staudt, L.M. Aggressive lymphomas. N. Engl. J. Med. 362, 1417-1429 (2010).
2. Alizadeh, A.A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000). (Pubitemid 30082188)
3. W right, G. et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 100, 9991-9996 (2003). (Pubitemid 37087056)
4. Dave, S.S. et al. Molecular diagnosis of Burkitt's lymphoma. N. Engl. J. Med. 354, 2431-2442 (2006). (Pubitemid 43855046)
5. Cattoretti, G. et al. Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. Blood 107, 3967-3975 (2006). (Pubitemid 43726803)
6. Savage, K.J. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102, 3871-3879 (2003). (Pubitemid 37486965)
7. Rosenwald, A. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198, 851-862 (2003). (Pubitemid 37152922)
8. Bergsagel, P.L. et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Natl. Acad. Sci. USA 93, 13931-13936 (1996). (Pubitemid 26424223)
9. Luo, J., Solimini, N.L. & Elledge, S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
10. Dent, A.L., Shaffer, A.L., Yu, X., Allman, D. & Staudt, L.M. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276, 589-592 (1997). (Pubitemid 27193682)
11. Ye, B.H. et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat. Genet. 16, 161-170 (1997).
12. Fukuda, T. et al. Disruption of the Bcl6 gene results in an impaired germinal center formation. J. Exp. Med. 186, 439-448 (1997). (Pubitemid 27332902)
13. Ye, B.H. et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262, 747-750 (1993). (Pubitemid 23350695)
14. Cattoretti, G. et al. BCL-6 protein is expressed in germinal-center B cells. Blood 86, 45-53 (1995).
15. Cattoretti, G. et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7, 445-455 (2005). (Pubitemid 40719128)
16. Shaffer, A.L. et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13, 199-212 (2000).
17. Tunyaplin, C. et al. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J. Immunol. 173, 1158-1165 (2004). (Pubitemid 38924291)
18. Phan, R.T., Saito, M., Basso, K., Niu, H. & Dalla-Favera, R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat. Immunol. 6, 1054-1060 (2005). (Pubitemid 41486191)
19. Ranuncolo, S.M. et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat. Immunol. 8, 705-714 (2007). (Pubitemid 46965346)
20. Phan, R.T. & Dalla-Favera, R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432, 635-639 (2004). (Pubitemid 39626271)
21. Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471, 189-195 (2011).
22. Bereshchenko, O.R., Gu, W. & Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 32, 606-613 (2002). (Pubitemid 35435172)
23. Saito, M. et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 106, 11294-11299 (2009).
24. Ci, W. et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B-cells and is deregulated in DLBCL. Blood (2009).
25. Polo, J.M. et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat. Med. 10, 1329-1335 (2004). (Pubitemid 40022714)
26. Cerchietti, L.C. et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17, 400-411 (2010).
27. Falini, B. et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95, 2084-2092 (2000). (Pubitemid 30151649)
28. Shaffer, A.L., Emre, N.C., Romesser, P.B. & Staudt, L.M. IRF4: Immunity. Malignancy! Therapy? Clin. Cancer Res. 15, 2954-2961 (2009).
29. Saito, M. et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 12, 280-292 (2007). (Pubitemid 47333420)
30. Lam, L.T. et al. Small molecule inhibitors of I-B kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin. Cancer Res. 11, 28-40 (2005). (Pubitemid 40075775)
31. Mittrücker, H.W. et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275, 540-543 (1997).
32. Sciammas, R. et al. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 25, 225-236 (2006). (Pubitemid 44224149)
33. Davis, R.E., Brown, K.D., Siebenlist, U. & Staudt, L.M. Constitutive nuclear factor B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861-1874 (2001). (Pubitemid 34028664)
34. Lenz, G. et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. USA 105, 13520-13525 (2008).
35. Pasqualucci, L. et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 203, 311-317 (2006). (Pubitemid 43290840)
36. Mandelbaum, J. et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 18, 568-579 (2010).
37. Tam, W. et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 107, 4090-4100 (2006). (Pubitemid 43726818)
38. Schmidlin, H. et al. Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression. Blood 112, 1804-1812 (2008).
39. Iqbal, J. et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 21, 2332-2343 (2007). (Pubitemid 350011706)
40. Kallies, A. et al. Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J. Exp. Med. 200, 967-977 (2004). (Pubitemid 39431122)
41. Kallies, A. et al. Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity 26, 555-566 (2007). (Pubitemid 46766640)
42. Calado, D.P. et al. Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 18, 580-589 (2010).
43. Shaffer, A.L. et al. IRF4 addiction in multiple myeloma. Nature 454, 226-231 (2008). (Pubitemid 351969894)
44. Staudt, L.M. Oncogenic activation of NF-κB. Cold Spring Harb. Perspect. Biol. 2, a000109 (2010).
45. Lenz, G. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676-1679 (2008). (Pubitemid 351432507)
46. Ngo, V.N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119 (2011).
47. Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459, 717-721 (2009).
48. Kato, M. et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 459, 712-716 (2009).
49. Schmitz, R. et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J. Exp. Med. 206, 981-989 (2009).
50. Novak, U. et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas. Blood 113, 4918-4921 (2009).
51. Sakai, A., Thieblemont, C., Wellmann, A., Jaffe, E.S. & Raffeld, M. PTEN gene alterations in lymphoid neoplasms. Blood 92, 3410-3415 (1998). (Pubitemid 28492352)
52. He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-833 (2005). (Pubitemid 40839734)
53. Xiao, C. et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 9, 405-414 (2008). (Pubitemid 351405110)
54. Davis, R.E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88-92 (2010).
55. Kloo, B. et al. Critical role of PI3K signaling for NF-κB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl. Acad. Sci. USA 108, 272-277 (2011).
56. Yang, J. et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB. Genes Dev. 21, 1396-1408 (2007). (Pubitemid 46871042)
57. Ngo, V.N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106-110 (2006).
58. Thome, M., Charton, J.E., Pelzer, C. & Hailfinger, S. Antigen receptor signaling to NF-κB via CARMA1, BCL10, and MALT1. Cold Spring Harb. Perspect. Biol. 2, a003004 (2010).
59. Sommer, K. et al. Phosphorylation of the CARMA1 linker controls NF-κB activation. Immunity 23, 561-574 (2005). (Pubitemid 41779479)
60. McCully, R.R. & Pomerantz, J.L. The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-κB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association. Mol. Cell. Biol. 28, 5668-5686 (2008).
61. Bidère, N. et al. Casein kinase 1αgoverns antigen-receptor-induced NF-κB activation and human lymphoma cell survival. Nature 458, 92-96 (2009).
62. Lamason, R.L., McCully, R.R., Lew, S.M. & Pomerantz, J.L. Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKCresponsive inhibitory domain. Biochemistry 49, 8240-8250 (2010).
63. Coornaert, B. et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-κB inhibitor A20. Nat. Immunol. 9, 263-271 (2008). (Pubitemid 351267323)
64. Rebeaud, F. et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat. Immunol. 9, 272-281 (2008). (Pubitemid 351267324)
65. Hailfinger, S. et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. USA 106, 19946-19951 (2009).
66. Ferch, U. et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 206, 2313-2320 (2009).
67. Zhou, H., Du, M.Q. & Dixit, V.M. Constitutive NF-κB activation by the t(11;18) (q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 7, 425-431 (2005). (Pubitemid 40719126)
68. Gyrd-Hansen, M. et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis. Nat. Cell Biol. 10, 1309-1317 (2008).
69. Rosebeck, S. et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-κB activation. Science 331, 468-472 (2011).
70. Lam, K.P., Kuhn, R. & Rajewsky, K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90, 1073-1083 (1997). (Pubitemid 27408521)
71. Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573-586 (2009).
72. Cariappa, A., Liou, H.C., Horwitz, B.H. & Pillai, S. Nuclear factor B is required for the development of marginal zone B lymphocytes. J. Exp. Med. 192, 1175-1182 (2000).
73. Thome, M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nat. Rev. Immunol. 4, 348-359 (2004). (Pubitemid 38649277)
74. Bahler, D.W. & Levy, R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc. Natl. Acad. Sci. USA 89, 6770-6774 (1992).
75. Fais, F. et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest. 102, 1515-1525 (1998). (Pubitemid 28492218)
76. Messmer, B.T. et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J. Exp. Med. 200, 519-525 (2004). (Pubitemid 39121908)
77. Chu, C.C. et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 115, 3907-3915 (2010).
78. Hervé, M. et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J. Clin. Invest. 115, 1636-1643 (2005). (Pubitemid 40814672)
79. Herishanu, Y. et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117, 563-574 (2011).
80. V aandrager, J.W. et al. DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma. Blood 92, 2871-2878 (1998).
81. Lossos, I.S. et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc. Natl. Acad. Sci. USA 97, 10209-10213 (2000).
82. Lenz, G. et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J. Exp. Med. 204, 633-643 (2007). (Pubitemid 46457085)
83. Ruminy, P. et al. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma. Leukemia 25, 681-688 (2011).
84. Engels, N. & Wienands, J. The signaling tool box for tyrosine-based costimulation of lymphocytes. Curr. Opin. Immunol. 23, 324-329 (2011).
85. Martin, S.W. & Goodnow, C.C. Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory. Nat. Immunol. 3, 182-188 (2002). (Pubitemid 34141449)
86. Dogan, I. et al. Multiple layers of B cell memory with different effector functions. Nat. Immunol. 10, 1292-1299 (2009).
87. Tolar, P., Hanna, J., Krueger, P.D. & Pierce, S.K. The constant region of the membrane immunoglobulin mediates B cell-receptor clustering and signaling in response to membrane antigens. Immunity 30, 44-55 (2009).
88. Rolli, V. et al. Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. Mol. Cell 10, 1057-1069 (2002). (Pubitemid 36001972)
89. Chan, V.W., Meng, F., Soriano, P., DeFranco, A.L. & Lowell, C.A. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 7, 69-81 (1997). (Pubitemid 27357266)
90. Gazumyan, A., Reichlin, A. & Nussenzweig, M.C. IgΒtyrosine residues contribute to the control of B cell receptor signaling by regulating receptor internalization. J. Exp. Med. 203, 1785-1794 (2006). (Pubitemid 44036283)
91. Ma, H. et al. Visualization of Syk-antigen receptor interactions using green fluorescent protein: differential roles for Syk and Lyn in the regulation of receptor capping and internalization. J. Immunol. 166, 1507-1516 (2001). (Pubitemid 32114629)
92. W ardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374-1377 (2003). (Pubitemid 37075812)
93. Yarkoni, Y., Getahun, A. & Cambier, J.C. Molecular underpinning of B-cell anergy. Immunol. Rev. 237, 249-263 (2010).
94. Gross, A.J., Lyandres, J.R., Panigrahi, A.K., Prak, E.T. & DeFranco, A.L. Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory pathway promotes B cell tolerance. J. Immunol. 182, 5382-5392 (2009).
95. Ding, B.B. et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111, 1515-1523 (2008). (Pubitemid 351213441)
96. Lam, L.T. et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111, 3701-3713 (2008).
97. Puente, X.S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011).
98. Jiang, Z. et al. Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis. Proc. Natl. Acad. Sci. USA 103, 10961-10966 (2006). (Pubitemid 44148401)
99. Hou, B. et al. Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 34, 375-384 (2011).
100. Marshak-Rothstein, A. & Rifkin, I.R. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol. 25, 419-441 (2007). (Pubitemid 46697913)
101. Isaacson, P.G., Norton, A.J. & Addis, B.J. The human thymus contains a novel population of B lymphocytes. Lancet 2, 1488-1491 (1987).
102. Rui, L. et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18, 590-605 (2010).
103. Skinnider, B.F. et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99, 618-626 (2002). (Pubitemid 34533100)
104. Shi, S. et al. JAK signaling globally counteracts heterochromatic gene silencing. Nat. Genet. 38, 1071-1076 (2006). (Pubitemid 44325935)
105. Dawson, M.A. et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461, 819-822 (2009).
106. Green, M.R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268-3277 (2010).
107. Steidl, C. et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471, 377-381 (2011).
108. Yap, D.B. et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451-2459 (2011).
109. Morin, R.D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010).
110. Sneeringer, C.J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. USA 107, 20980-20985 (2010).
111. Calin, G.A. et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 99, 15524-15529 (2002). (Pubitemid 35403967)
112. Klein, U. et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17, 28-40 (2010).
113. Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011).
114. Irish, J.M. et al. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc. Natl. Acad. Sci. USA 107, 12747-12754 (2010).